Aegerion Pharmaceuticals Company Profile (NASDAQ:AEGR)

About Aegerion Pharmaceuticals (NASDAQ:AEGR)

Aegerion Pharmaceuticals logoAegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:AEGR
  • CUSIP: 00767E10
  • Web: www.aegerion.com
Average Prices:
  • 50 Day Moving Avg: $1.93
  • 200 Day Moving Avg: $1.81
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.35
  • P/E Growth: 0.00
Profitability:
  • Net Margins: -106.62%
  • Return on Equity: -287.49%
  • Return on Assets: -30.75%
Debt:
  • Debt-to-Equity Ratio: -19.22%
  • Current Ratio: 1.02%
  • Quick Ratio: 0.67%
Misc:
  • Beta: 0.5
 

Frequently Asked Questions for Aegerion Pharmaceuticals (NASDAQ:AEGR)

What is Aegerion Pharmaceuticals' stock symbol?

Aegerion Pharmaceuticals trades on the NASDAQ under the ticker symbol "AEGR."

How were Aegerion Pharmaceuticals' earnings last quarter?

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) posted its earnings results on Monday, May, 16th. The company reported ($1.72) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.58) by $1.14. The business earned $35.70 million during the quarter, compared to analyst estimates of $43 million. Aegerion Pharmaceuticals had a negative net margin of 106.62% and a negative return on equity of 287.49%. Aegerion Pharmaceuticals's revenue was down 39.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.55) earnings per share. View Aegerion Pharmaceuticals' Earnings History.

Where is Aegerion Pharmaceuticals' stock going? Where will Aegerion Pharmaceuticals' stock price be in 2017?

2 brokers have issued 12 month target prices for Aegerion Pharmaceuticals' stock. Their forecasts range from $1.50 to $1.50. On average, they expect Aegerion Pharmaceuticals' share price to reach $1.50 in the next year. View Analyst Ratings for Aegerion Pharmaceuticals.

What are analysts saying about Aegerion Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aegerion Pharmaceuticals stock:

  • 1. Cowen and Company analysts commented, "Due to the November 29, 2016 merger of Aegerion Pharmaceuticals, Inc." (11/30/2016)
  • 2. According to Zacks Investment Research, "Aegerion’s third-quarter results were encouraging, with the company reporting a narrower-than-expected loss and revenues surpassing expectations. Aegerion’s upcoming merger agreement with QLT Inc. is a big positive. It will leverage the company’s development and commercial capabilities to provide transformative treatments to patients suffering from rare but debilitating diseases. The agreement comes at a time when the company's lead drug, Juxtapid, is facing challenges due to the launch of PCSK9 inhibitors in the U.S. The company added another drug, Myalept from AstraZeneca, which boosted its portfolio. However, Aegerion is facing reimbursement hurdles for Myalept as prior authorizations are taking longer than expected and payers are requesting additional data. Moreover, the decision to withdraw Juxtapid from the EU is disappointing." (11/21/2016)

Who are some of Aegerion Pharmaceuticals' key competitors?

How do I buy Aegerion Pharmaceuticals stock?

Shares of Aegerion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aegerion Pharmaceuticals stock cost?

One share of Aegerion Pharmaceuticals stock can currently be purchased for approximately $1.87.

Analyst Ratings

Consensus Ratings for Aegerion Pharmaceuticals (NASDAQ:AEGR) (?)
Ratings Breakdown: 2 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $1.50 (19.79% downside)

Analysts' Ratings History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/30/2016Cowen and CompanyReiterated RatingHold$1.50N/AView Rating Details
11/11/2016JPMorgan Chase & Co.Initiated CoverageHoldN/AView Rating Details
5/17/2016Leerink SwannBoost Price TargetOutperform$6.00 -> $15.00N/AView Rating Details
2/12/2016Bank of America CorpDowngradeNeutral -> Underperform$6.00N/AView Rating Details
12/21/2015GuggenheimUpgradeSell -> Buy$7.00 -> $13.00N/AView Rating Details
11/10/2015Jefferies Group LLCLower Price TargetBuy$26.00 -> $16.00N/AView Rating Details
5/26/2015Needham & Company LLCReiterated RatingHoldN/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Earnings by Quarter for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Earnings History by Quarter for Aegerion Pharmaceuticals (NASDAQ:AEGR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/16/2016Q1($0.58)($1.72)$43.00 million$35.70 millionViewListenView Earnings Details
2/25/2016Q4($0.89)($0.69)$47.74 million$49.00 millionViewListenView Earnings Details
11/9/2015Q315($0.42)($0.34)$59.72 million$67.30 millionViewN/AView Earnings Details
8/5/2015Q2($0.27)($0.01)$58.98 million$64.20 millionViewN/AView Earnings Details
10/30/2014Q314($0.18)($0.12)$48.60 million$43.70 millionViewN/AView Earnings Details
7/29/2014Q214($0.41)($0.33)$35.40 million$36.00 millionViewListenView Earnings Details
5/6/2014Q1($0.35)($0.54)$33.58 million$27.00 millionViewListenView Earnings Details
2/26/2014Q413($0.30)($0.14)$24.51 million$24.50 millionViewListenView Earnings Details
10/29/2013Q313($0.50)($0.43)$13.07 million$16.30 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.62)($0.66)$4.27 million$6.50 millionViewN/AView Earnings Details
11/7/2012Q312($0.56)($0.59)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Current Year EPS Consensus Estimate: $-3.10 EPS
Next Year EPS Consensus Estimate: $-0.43 EPS

Dividends

Dividend History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 84.87%
Insider Trades by Quarter for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Institutional Ownership by Quarter for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Insider Trades by Quarter for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/13/2016Healthcare Master Fun BroadfinMajor ShareholderBuy75,000$1.75$131,250.00View SEC Filing  
9/12/2016Healthcare Master Fun BroadfinMajor ShareholderBuy276,000$1.66$458,160.00View SEC Filing  
8/19/2014Mark J FitzpatrickCFOBuy1,150$30.64$35,236.00View SEC Filing  
7/31/2014Marc D BeerCEOBuy10,000$33.65$336,500.00View SEC Filing  
6/3/2014Marc D BeerCEOBuy10,000$30.12$301,200.00View SEC Filing  
5/27/2014Marc D BeerCEOBuy10,000$31.59$315,900.00View SEC Filing  
5/20/2014Marc BeerCEOBuy10,000$30.53$305,300.00View SEC Filing  
5/8/2014Anne VanlentDirectorBuy4,000$33.78$135,120.00View SEC Filing  
5/8/2014Marc BeerCEOBuy30,000$35.31$1,059,300.00View SEC Filing  
4/30/2014Craig FraserInsiderSell2,250$43.55$97,987.50View SEC Filing  
3/31/2014Craig FraserInsiderSell2,250$46.20$103,950.00View SEC Filing  
3/14/2014Mark SumerayInsiderSell2,000$51.34$102,680.00View SEC Filing  
2/11/2014Craig FraserInsiderSell2,250$67.00$150,750.00View SEC Filing  
12/16/2013Mark SumerayInsiderSell2,000$66.34$132,680.00View SEC Filing  
10/30/2013Marc D BeerCEOSell40,000$87.79$3,511,600.00View SEC Filing  
10/29/2013Sandford D SmithDirectorSell2,502$95.00$237,690.00View SEC Filing  
10/15/2013Mark SumerayInsiderSell2,000$80.33$160,660.00View SEC Filing  
10/7/2013Mark SumerayInsiderSell3,500$93.17$326,095.00View SEC Filing  
9/16/2013Mark SumerayInsiderSell2,000$89.77$179,540.00View SEC Filing  
9/5/2013Perceptive Advisors LlcMajor ShareholderSell750,000$89.20$66,900,000.00View SEC Filing  
8/21/2013David ScheerDirectorSell20,000$84.58$1,691,600.00View SEC Filing  
8/16/2013Mark SumerayInsiderSell2,000$88.71$177,420.00View SEC Filing  
8/15/2013Marc BeerCEOSell60,000$88.54$5,312,400.00View SEC Filing  
8/14/2013Mark FitzpatrickCFOSell7,500$93.44$700,800.00View SEC Filing  
8/12/2013Sandford SmithDirectorSell10,000$92.32$923,200.00View SEC Filing  
7/15/2013Mark SumerayInsiderSell2,000$78.77$157,540.00View SEC Filing  
6/17/2013Mark SumerayInsiderSell6,000$65.27$391,620.00View SEC Filing  
5/15/2013Mark SumerayInsiderSell6,000$47.32$283,920.00View SEC Filing  
2/1/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$27.79$1,389,500.00View SEC Filing  
1/18/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$27.62$1,381,000.00View SEC Filing  
1/17/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$26.73$1,336,500.00View SEC Filing  
1/11/2013Perceptive Advisors LlcMajor ShareholderBuy475,000$27.07$12,858,250.00View SEC Filing  
12/4/2012Perceptive Advisors LlcMajor ShareholderBuy20,000$21.27$425,400.00View SEC Filing  
11/29/2012Perceptive Advisors LlcMajor ShareholderBuy30,000$22.71$681,300.00View SEC Filing  
11/28/2012Perceptive Advisors LlcMajor ShareholderBuy150,000$21.25$3,187,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Latest Headlines for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Source:

Social

Chart

Aegerion Pharmaceuticals (AEGR) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff